Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Background: Visceral adiposity index (VAI), a surrogate marker of adiposity and insulin resistance, has been demonstrated to be significantly related to cardiovascular disease. It remains indistinct whether VAI predicts adverse prognosis after percutaneous coronary intervention (PCI) for patients wi...

Full description

Bibliographic Details
Main Authors: Qi Zhao, Yu-Jing Cheng, Ying-Kai Xu, Zi-Wei Zhao, Chi Liu, Tie-Nan Sun, Yu-Jie Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.735637/full
_version_ 1819038712319705088
author Qi Zhao
Yu-Jing Cheng
Ying-Kai Xu
Zi-Wei Zhao
Chi Liu
Tie-Nan Sun
Yu-Jie Zhou
author_facet Qi Zhao
Yu-Jing Cheng
Ying-Kai Xu
Zi-Wei Zhao
Chi Liu
Tie-Nan Sun
Yu-Jie Zhou
author_sort Qi Zhao
collection DOAJ
description Background: Visceral adiposity index (VAI), a surrogate marker of adiposity and insulin resistance, has been demonstrated to be significantly related to cardiovascular disease. It remains indistinct whether VAI predicts adverse prognosis after percutaneous coronary intervention (PCI) for patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and type 2 diabetes mellitus (T2DM).Methods: A total of 798 participants who met the enrollment criteria were finally brought into this study. VAI was determined by waist circumference, body mass index, fasting triglyceride, and high-density lipoprotein cholesterol as previously reported. Adverse prognosis included all-cause death, non-fatal myocardial infarction, non-fatal ischemic stroke, and ischemia-driven revascularization, the composite of which was defined as the primary endpoint.Results: Higher VAI maintained as a significant and independent risk predictor for the primary endpoint, regardless of the adjustment for the various multivariate models [hazard ratio (95% CI) for fully adjusted model: 2.72 (2.02–3.68), p < 0.001]. The predictive value of VAI was further confirmed in sensitivity analysis where VAI was taken as a continuous variate. There was a dose-response relationship of VAI with the risk of the primary endpoint (p for overall association < 0.001). Moreover, the ability of VAI on the prediction of the primary endpoint was consistent between subgroups stratified by potential confounding factors (all p for interaction > 0.05). VAI exhibited a significant incremental effect on risk stratification for the primary endpoint beyond existing risk scores, expressed as increased Harrell's C-index, significant continuous net reclassification improvement, and significant integrated discrimination improvement.Conclusion: VAI is a significant indicator for predicting worse prognosis and plays an important role in risk stratification among patients with NSTE-ACS and T2DM undergoing elective PCI. The present findings require further large-scale, prospective studies to confirm.
first_indexed 2024-12-21T08:41:40Z
format Article
id doaj.art-408dcdefabf84588b18d93a96321cd14
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-12-21T08:41:40Z
publishDate 2021-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-408dcdefabf84588b18d93a96321cd142022-12-21T19:09:56ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-11-01810.3389/fcvm.2021.735637735637Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary InterventionQi ZhaoYu-Jing ChengYing-Kai XuZi-Wei ZhaoChi LiuTie-Nan SunYu-Jie ZhouBackground: Visceral adiposity index (VAI), a surrogate marker of adiposity and insulin resistance, has been demonstrated to be significantly related to cardiovascular disease. It remains indistinct whether VAI predicts adverse prognosis after percutaneous coronary intervention (PCI) for patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and type 2 diabetes mellitus (T2DM).Methods: A total of 798 participants who met the enrollment criteria were finally brought into this study. VAI was determined by waist circumference, body mass index, fasting triglyceride, and high-density lipoprotein cholesterol as previously reported. Adverse prognosis included all-cause death, non-fatal myocardial infarction, non-fatal ischemic stroke, and ischemia-driven revascularization, the composite of which was defined as the primary endpoint.Results: Higher VAI maintained as a significant and independent risk predictor for the primary endpoint, regardless of the adjustment for the various multivariate models [hazard ratio (95% CI) for fully adjusted model: 2.72 (2.02–3.68), p < 0.001]. The predictive value of VAI was further confirmed in sensitivity analysis where VAI was taken as a continuous variate. There was a dose-response relationship of VAI with the risk of the primary endpoint (p for overall association < 0.001). Moreover, the ability of VAI on the prediction of the primary endpoint was consistent between subgroups stratified by potential confounding factors (all p for interaction > 0.05). VAI exhibited a significant incremental effect on risk stratification for the primary endpoint beyond existing risk scores, expressed as increased Harrell's C-index, significant continuous net reclassification improvement, and significant integrated discrimination improvement.Conclusion: VAI is a significant indicator for predicting worse prognosis and plays an important role in risk stratification among patients with NSTE-ACS and T2DM undergoing elective PCI. The present findings require further large-scale, prospective studies to confirm.https://www.frontiersin.org/articles/10.3389/fcvm.2021.735637/fullvisceral adiposity indexinsulin resistancetype 2 diabetes mellitusnon-ST-segment elevation acute coronary syndromepercutaneous coronary interventionprognosis
spellingShingle Qi Zhao
Yu-Jing Cheng
Ying-Kai Xu
Zi-Wei Zhao
Chi Liu
Tie-Nan Sun
Yu-Jie Zhou
Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
Frontiers in Cardiovascular Medicine
visceral adiposity index
insulin resistance
type 2 diabetes mellitus
non-ST-segment elevation acute coronary syndrome
percutaneous coronary intervention
prognosis
title Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
title_full Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
title_fullStr Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
title_full_unstemmed Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
title_short Visceral Adiposity Index Plays an Important Role in Prognostic Prediction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
title_sort visceral adiposity index plays an important role in prognostic prediction in patients with non st segment elevation acute coronary syndrome and type 2 diabetes mellitus undergoing percutaneous coronary intervention
topic visceral adiposity index
insulin resistance
type 2 diabetes mellitus
non-ST-segment elevation acute coronary syndrome
percutaneous coronary intervention
prognosis
url https://www.frontiersin.org/articles/10.3389/fcvm.2021.735637/full
work_keys_str_mv AT qizhao visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT yujingcheng visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT yingkaixu visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT ziweizhao visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT chiliu visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT tienansun visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention
AT yujiezhou visceraladiposityindexplaysanimportantroleinprognosticpredictioninpatientswithnonstsegmentelevationacutecoronarysyndromeandtype2diabetesmellitusundergoingpercutaneouscoronaryintervention